Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 6/20 | 0.63 |
| ▸ | MMP3 | P08254 | 5/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.58 |
| ▸ | HRH2 | P25021 | 9/20 | 0.58 |
| ▸ | HRH1 | P35367 | 9/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.58 |
| ▸ | MMP9 | P14780 | 1/20 | 0.58 |
| ▸ | MMP13 | P45452 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9786700 | 0.95 | MMP3 (0.61) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL1618099 | 0.94 | ALDH1A1 (0.56) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL5091513 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL5097477 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL5097462 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL9169148 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL5097481 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL4594927 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL5091525 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 | |
| SCHEMBL5090877 | 0.93 | HDAC1 (0.62) | MMP2MMP3HRH3HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-61047455-A | — | — | None | — | — | JP | disclosed |
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| EP-2562155-B1 | HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO LTD (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-9499477-B2 | Hydroxamic acid derivative | TOYAMA CHEMICAL CO., LTD. (JP) | 2016-11-22 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9073821-B2 | Hydroxamic acid derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2015-07-07 | — | — | US | disclosed |
| US-6180028-B1 | ACRYLATED ESTERS | ASAHI GLASS COMPANY LTD. (JP) | 2001-01-30 | — | — | US | disclosed |
| EP-0955348-A1 | LIQUID-CRYSTAL COMPOSITION AND POLYMERIC LIQUID CRYSTAL OBTAINED BY POLYMERIZING THE SAME | Asahi Glass Company Ltd. (JP) | 1999-11-10 | — | — | EP | disclosed |
| EP-0679633-B1 | Diaminobenzene derivatives and polyimides prepared therefrom | NISSAN CHEMICAL IND LTD (JP) | 1999-11-03 | — | — | EP | disclosed |
| US-5861534-A | CHEMICAL INTERMEDIATES | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1999-01-19 | — | — | US | disclosed |
| US-5665856-A | Diaminobenzene derivatives and polyimides prepared therefrom | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-09 | — | — | US | disclosed |
| EP-0679633-A1 | Diaminobenzene derivatives and polyimides prepared therefrom | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-11-02 | — | — | EP | disclosed |
| EP-0171794-B1 | ALCOHOL DERIVATIVES AND LIQUID CRYSTAL COMPOSITION CONTAINING THEM | Chisso Corporation (JP) | 1988-06-22 | — | — | EP | disclosed |
| US-4654162-A | Alcohol derivatives | CHISSO CORPORATION (JP) | 1987-03-31 | — | — | US | disclosed |
| JP-S6147455-A | 4-CYANO-4'-(HYDROXYALKOXY)BIPHENYL | CHISSO CORP | 1986-03-07 | — | — | JP | disclosed |
| EP-0171794-A1 | Alcohol derivatives and liquid crystal composition containing them | Chisso Corporation (JP) | 1986-02-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225335-A1 | NOVEL HYDROXAMIC ACID DERIVATIVE | LCT, AGXT, HDAC9 | MMP2 111/4885MMP3 194/4885HRH3 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.